Merck & Co (NY:MRK)

Merck & Company Inc. (NYSE: MRK) Records 52-Week High Thursday Morning

February 01, 2024

Via Investor Brand Network

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

February 01, 2024

The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance

IBM, Verizon, Merck stocks lead Dow to new highs

January 31, 2024

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Topics Stocks

January 27, 2024

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

January 26, 2024

Merck Announces Second-Quarter 2024 Dividend

January 23, 2024

Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1

January 19, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

January 16, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

January 12, 2024

NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution

January 12, 2024

Via Investor Brand Network

Topics Intellectual Property

AstraZeneca: Rebound in 2024 with double-digit earnings growth

January 11, 2024

AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition

Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.

January 08, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Merck, the Dow's hottest stock, gets set to report Q4 financials

January 08, 2024

EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END

Topics Stocks

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

January 08, 2024

Via Investor Brand Network

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

January 08, 2024

Via FinancialNewsMedia

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

January 08, 2024

Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.

Are defensive sectors ready to outshine growth in 2024?

January 06, 2024

With interest in Moderna Inc. stock picking up alongside news flow, investors could be in for some very healthy 2024 gains.

3 reasons 2024 Moderna shareholders may party like it's 2021

January 05, 2024

Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline

January 05, 2024

Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

The torrid stock market rally cooled down a little bit heading into the extended holiday weekend; we wish you a Happy Holiday season with friends and family

MarketBeat Week in Review – 12/18 - 12/22

December 23, 2023

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Topics Economy

December 22, 2023

From Daiichi Sankyo

Merck Provides U.S. Regulatory Update on Gefapixant

December 20, 2023

Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference

December 20, 2023

FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults

December 19, 2023

As the market soars to new heights, C4 Therapeutics (NASDAQ: CCCC) has become the latest small-cap stock to explode higher in price and volume.

C4 Therapeutics blasts off: what's next?

December 18, 2023

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer

Topics ETFs

December 18, 2023

FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

December 15, 2023

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI

December 14, 2023